Theravance COVID-19 therapy shows potential in mid-stage study

 

• TD-0903, an inhaled pan-JAK inhibitor being developed by Theravance Biopharma (TBPH -3.4%) has demonstrated a favorable impact in hospitalized patients with severe COVID-19, according to data from a Phase 2 trial.
• The findings published in a pre-print pending a peer-review indicate that in the trial where 25 patients were randomized to receive TD 0903 or placebo, TD-0903 was generally well tolerated with no treatment-related serious adverse events.
• The clinically favorable numerical trends included lower mortality, shorter hospitalization, better oxygenation as well as what researchers identified as improved 8-point clinical status.
• Based on Part 1 of this phase 2 trial, the paper concluded the potential of TD-0903 in the treatment of patients with severe COVID-19.
• Theravance Biopharma initiated the dosing of Part 1 of Phase 2 study of TD-0903 in June and the second part of the trial, a larger multi-center study is currently in progress involving 198 hospitalized patients with COVID-19.

https://newsfilter.io/a/97e880efac3fd062cb6434198202bce8